+

WO2010068810A3 - Certain substituted amides, method of making, and method of use thereof - Google Patents

Certain substituted amides, method of making, and method of use thereof Download PDF

Info

Publication number
WO2010068810A3
WO2010068810A3 PCT/US2009/067575 US2009067575W WO2010068810A3 WO 2010068810 A3 WO2010068810 A3 WO 2010068810A3 US 2009067575 W US2009067575 W US 2009067575W WO 2010068810 A3 WO2010068810 A3 WO 2010068810A3
Authority
WO
WIPO (PCT)
Prior art keywords
making
btk
substituted amides
certain substituted
formula
Prior art date
Application number
PCT/US2009/067575
Other languages
French (fr)
Other versions
WO2010068810A2 (en
Inventor
Peter A. Blomgren
Kevin S. Currie
Scott A. Mitchell
David R. Brittelli
Aaron C. Schmitt
Jr. Antonio J. Barbosa
Original Assignee
Cgi Pharmaceuticals, Inc.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cgi Pharmaceuticals, Inc., Genentech, Inc. filed Critical Cgi Pharmaceuticals, Inc.
Publication of WO2010068810A2 publication Critical patent/WO2010068810A2/en
Publication of WO2010068810A3 publication Critical patent/WO2010068810A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and / or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
PCT/US2009/067575 2008-12-10 2009-12-10 Certain substituted amides, method of making, and method of use thereof WO2010068810A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12140308P 2008-12-10 2008-12-10
US61/121,403 2008-12-10

Publications (2)

Publication Number Publication Date
WO2010068810A2 WO2010068810A2 (en) 2010-06-17
WO2010068810A3 true WO2010068810A3 (en) 2011-02-10

Family

ID=41559565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/067575 WO2010068810A2 (en) 2008-12-10 2009-12-10 Certain substituted amides, method of making, and method of use thereof

Country Status (1)

Country Link
WO (1) WO2010068810A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552514T3 (en) * 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Bicyclic Piperazine Compounds
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
TW201414737A (en) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 Imidazotriazinecarbonitriles useful as kinase inhibitors
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
JO3377B1 (en) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co Pyridinyl and fused pyridinyl triazolone derivatives
LT2989106T (en) 2013-04-25 2017-04-10 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
PL3702373T3 (en) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2016165831A1 (en) 2015-04-17 2016-10-20 Curevac Ag Lyophilization of rna
EP3916091A3 (en) 2015-05-20 2022-03-30 CureVac AG Dry powder composition comprising long-chain rna
WO2016184576A2 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
WO2017173111A1 (en) 2016-03-31 2017-10-05 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
JP6993056B2 (en) 2016-07-05 2022-02-15 ベイジーン リミテッド Combination of PD-1 antagonist and RAF inhibitor for cancer treatment
TWI865873B (en) 2016-08-16 2024-12-11 瑞士商百濟神州瑞士有限責任公司 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
PT3500299T (en) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Use of a combination comprising a btk inhibitor for treating cancers
JP2019529419A (en) 2016-09-19 2019-10-17 エムイーアイ ファーマ，インク． Combination therapy
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
WO2019001417A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN110997677A (en) 2017-08-12 2020-04-10 百济神州有限公司 Btk inhibitors with improved dual selectivity
CN111801334B (en) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors
CN111825675B (en) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 ROCK inhibitor and preparation method and application thereof
TW202446397A (en) 2019-06-10 2024-12-01 瑞士商百濟神州瑞士有限責任公司 An oral solid tablet containing Brutton's tyrosine kinase inhibitor and a preparation method thereof
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038314A2 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008116064A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038314A2 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008116064A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FAUCI, A.S.; BRAUNWALD, E.; ISSELBACHER, K.J.; WILSON, J.D.; MARTIN, J.>B.; KASPER, D.L.; HAUSER, S.L.; LONGO, D.L.: "Harrison's Principles of Internal Medicine", 1998, MCGRAW-HILL, ISBN: 0070202915, XP002566174, 1 *

Also Published As

Publication number Publication date
WO2010068810A2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
WO2010068810A3 (en) Certain substituted amides, method of making, and method of use thereof
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2008033857A3 (en) Substituted amides, method of making, and method of use thereof
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
MX2009002649A (en) Certain substituted amides, method of making, and method of use thereof.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2006099075A3 (en) Certain substituted amides, method of making, and method of use thereof
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2006059245A3 (en) Compounds for the treatment of cns and amyloid associated diseases
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
IN2015DN04175A (en)
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
EA200201276A1 (en) ARYLMETYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2009038412A3 (en) Beta-secretase inhibiting compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09768590

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09768590

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载